Table 2

ORs and 95% CI for lifetime exposure and for exposure before age 36 years, per 10-year increase of occupational exposure to any intensity of two organic solvents indices, according to tumour hormonal phenotypes^* postmenopausal breast cancer, Montreal, Canada, 1996–7

	All tumours				ER+/PR+				ER−/PR−				ER+/PR−
	N=310				N=84				N=82
	Age-adjusted		Fully adjusted†		Age-adjusted		Fully adjusted†		Age-adjusted		Fully adjusted†		Age-adjusted		Fully adjusted†
	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Lifetime exposure‡
Volatile organic liquids	1.13	0.99 to 1.28	1.07	0.93 to 1.24	1.12	0.97 to 1.30	1.09	0.91 to 1.29	1.07	0.83 to 1.38	0.97	0.73 to 1.29	1.18	0.93 to 1.51	1.14	0.85 to 1.51
Organic solvents with reactive metabolites	1.12	0.81 to 1.53	1.14	0.80 to 1.62	1.05	0.71 to 1.55	1.12	0.71 to 1.76	1.08	0.58 to 2.00	1.18	0.60 to 2.31	1.39	0.81 to 2.37	1.73	0.88 to 3.39
Exposure before age 36 years
Volatile organic liquids	1.30	0.98 to 1.74	1.14	0.82 to 1.59	1.26	0.90 to 1.76	1.14	0.77 to 1.68	1.04	0.57 to 1.91	0.88	0.43 to 1.80	1.53	0.90 to 2.61	1.48	0.77 to 2.83
Organic solvents with reactive metabolites	1.29	0.69 to 2.39	1.30	0.65 to 2.60	1.22	0.58 to 2.53	1.27	0.56 to 2.90	0.78	0.17 to 3.50	0.89	0.17 to 4.58	2.05	0.81 to 5.22	3.31	1.07 to 10.20

↵* Oestrogen receptor-negative and progesterone-receptor-positive tumours not reported here because of small numbers (N=16).
↵† Adjusted for age, family history, age at oophorectomy, education, ethnicity, age at menarche, oral contraceptive use, duration of hormone replacement therapy use, total duration of breastfeeding, smoking status, alcohol consumption status, body mass index, age at first full-term pregnancy (≥35 weeks) and proxy respondent status.
↵‡ Lifetime exposures were computed by adding up hours of exposure to medium or high levels of any of the solvents composing each index, across all jobs until the date of diagnosis, regardless of age at exposure.
ER+/PR+, oestrogen and progesterone receptor-positive tumours; ER−/PR−; oestrogen and progesterone receptor-negative tumours; ER+/PR−, oestrogen receptor-positive and progesterone receptor-negative tumours.